Strides Pharma acquires FDA OK for generic butalbital, acetaminophen and caffeine
Patients seeking relief of the symptom complex of tension (or muscle contraction) headache will soon have a new generic treatment.
Strides Pharma has received the Food and Drug Administration’s blessing for butalbital, acetaminophen, and caffeine tablets in a dosage strength of 50 mg/325 mg/40 mg.
The product is the generic of Actavis Laboratories’ butalbital, acetaminophen, and caffeine tablets.
It had a market value of roughly $40 million, according to IQVIA July 2020 data.